Home / Business and Economy / Harbour BioMed Eyes $1B+ Payout in BMS Collaboration
Harbour BioMed Eyes $1B+ Payout in BMS Collaboration
17 Dec
Summary
- Harbour BioMed and Bristol Myers Squibb signed a global strategic partnership.
- The deal focuses on multi-specific antibody discovery and development.
- Harbour BioMed could receive over $1 billion in milestone payments.
Harbour BioMed and Bristol Myers Squibb have established a significant multi-year, worldwide strategic partnership focused on the discovery and development of multi-specific antibodies. This collaboration aims to accelerate the progress of antibody programs, utilizing Harbour BioMed's advanced Harbour Mice fully human antibody technology platform.
The agreement positions Harbour BioMed to potentially receive substantial financial benefits, including initial payments totaling $90 million and further development and commercial milestone payments that could exceed $1.035 billion. Additionally, Harbour BioMed may be eligible for tiered royalties on all future programs that Bristol Myers Squibb chooses to advance.
This strategic alliance underscores Harbour BioMed's commitment to expanding its pipeline in oncology and immunology. The collaboration also presents an opportunity to utilize Harbour BioMed's development capabilities for early clinical trials in China, potentially expediting the delivery of innovative therapies to patients globally.
